Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions

Published:2023-01-01 Issue:1 Volume:207 Page:102-105
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Khor Yet H.¹²³⁴^ORCID,Farooqi Malik⁵,Hambly Nathan⁵,Kolb Martin⁵^ORCID,Ryerson Christopher J.⁶⁷,Assayag Deborah,Cox Gerard,Fell Charlene D.,Fisher Jolene H.,Gershon Andrea S.,Goh Nicole,Halayko Andrew J.,Johannson Kerri A.,Khalil Nasreen,Lok Stacey,Manganas Helene,Marcoux Veronica,Morisset Julie,Sadatsafavi Mohsen,Shapera Shane,To Teresa,Wilcox Pearce G.,Wong Alyson W.

Affiliation:

1. Monash UniversityMelbourne, Victoria, Australia

2. Austin HealthHeidelberg, Victoria, Australia

3. Institute for Breathing and SleepHeidelberg, Victoria, Australia

4. University of MelbourneMelbourne, Victoria, Australia

5. McMaster UniversityHamilton, Ontario, Canada

6. University of British ColumbiaVancouver, British Columbia, Canada

7. St. Paul’s HospitalVancouver, British Columbia, Canada

Funder

National Health and Medical Research Council

The Canadian Registry for Pulmonary Fibrosis

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.202205-0910LE

Reference7 articles.

1. Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review

2. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry

3. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

4. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

5. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research priorities for progressive pulmonary fibrosis in the UK;BMJ Open Respiratory Research;2024-09

2. Application of the 2022 American Thoracic/European Respiratory Society/Japanese Respiratory Society/Associatión Latinoamericana de Tórax (ATS/ERS/JRS/ALAT) idiopathic pulmonary fibrosis and progressive pulmonary fibrosis clinical practice guideline to a Canadian population: An opinion piece;Canadian Journal of Respiratory, Critical Care, and Sleep Medicine;2024-07-03

3. Multiomic analysis of monocyte-derived alveolar macrophages in idiopathic pulmonary fibrosis;Journal of Translational Medicine;2024-06-27

4. Outcome after nintedanib therapy for fibrosing interstitial lung disease in patients without dyspnea;2024-06-25

5. Interstitial lung disease was suspected, but biopsy revealed pulmonary lymphangitis carcinomatosa;European Clinical Respiratory Journal;2024-06-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3